12RS HB377
LRC Seal

HB377

12RS

WWW Version

The hyperlink to a bill draft that precedes a summary contains the most recent version (Introduced/GA/Enacted) of the bill. If the session has ended, the hyperlink contains the latest version of the bill at the time of sine die adjournment. Note that the summary pertains to the bill as introduced, which is often different from the most recent version.


HB 377/FN/LM (BR 354) - A. Wuchner, B. DeWeese, T. Burch, J. Carney, J. Hoover, M. Rader, S. Santoro, B. Waide, S. Westrom

     AN ACT relating to the substitution of opioids in pharmacies and declaring an emergency.
     Create a new section of KRS 315 to define terms; require the Board of Pharmacy to publish and, in some cases, determine qualifying drugs for a list of opioid analgesics that incorporate tamper-resistance technologies and prohibit substitution or interchange of those drugs without the pharmacy verifying that the substitute provides substantially similar tamper-resistance properties as determined by the board or without obtaining written consent of the prescriber; EMERGENCY.

HB 377 - AMENDMENTS


     HCS/FN - Retain original provisions except exempt pharmacists in hospital based pharmacies filling prescriptions for inpatient care from compliance and allow a practitioner to prohibit substitution when the practitioner determines that substitution is not in the best interest of the patient.
     HFA (1, R. Damron) - Retain original provisions except clarify that opioid analgesic drugs shall continue to be available to nursing home and hospice care patients without modification.
     HFA (2, R. Damron) - Retain original provisions except clarify that the FDA must determine that a drug incorporates tamper-resistant technologies; require that the pharmacy board promulgate an administrative regulation determining which drugs incorporate these technologies; require that the drug bear a labeling claim relating to its reduction of tampering or abuse potential; require that the pharmacy board create a list of any available drugs determined by the FDA to be substantially similar to other opioid analgesic drugs incorporating a tamper-resistant technology.
     HFA (3, A. Wuchner) - Retain provisions of HCS1; delete the emergency clause.
     HFA (4/Title, A. Wuchner) - Make title amendment.

     Feb 8-introduced in House
     Feb 9-to Health & Welfare (H)
     Feb 13-posted in committee
     Feb 23-reported favorably, 1st reading, to Consent Calendar with Committee Substitute
     Feb 24-2nd reading, to Rules
     Feb 27-posted for passage in the Consent Orders of the Day for Wednesday, February 29, 2012
     Feb 28-floor amendment (1) filed to Committee Substitute
     Feb 29-taken from the Consent Orders of the Day, placed in the Regular Orders of the Day
     Mar 7-floor amendment (2) filed to Committee Substitute
     Mar 9-floor amendment (3) filed to Committee Substitute, floor amendment (4-title) filed
     Mar 23-taken from the Regular Orders of the Day; recommitted to Appropriations & Revenue (H)


Legislature Home Page | Record Front Page